# Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part II

> **NCT01598415** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 130 (actual)

## Conditions studied

- Knee Osteoarthritis

## Interventions

- **DRUG:** SAR113945
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01598415
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2014-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01598415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01598415, "Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part II". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01598415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*